Department of Life Sciences - Studentin betrachtet eine Probe durch ein Mikroskop

Research – Department of Science and Technology

The Department of Science and Technology acts as an international academic competence centre of interdisciplinary education and research.

From disease models to drug development

The Department of Life Sciences aims to facilitate communication and interaction between researchers looking at various aspects of applied biomedicine research. We focus on cancer, immune system disorders, toxicology, drug research and the latest bioprocess engineering techniques, to name just a few of our areas of expertise.

The interdisciplinary team is optimally positioned to move rapidly from disease modelling to the identification and development of drugs and lead compounds. Moreover, we have established an international scientific network including universities, research institutes, small and medium-sized enterprises and global pharmaceutical players.

Biologie Studenten im Labor
Zwei Biologie Studenten mit einer Zentrifuge
Biologie Studentin nimmt eine Probe mit einer Pipette

Research focus areas: Department of Science and Technology

In the Department of Science and Technology we concentrate our research activities on the following main research focuses


In the research focus medical biotechnology, we deal with the identification, validation and optimisation of molecules and biologics, which can be used in personalised medicine, antiviral therapies or as biomarkers. Within this focus, many methods and resources have been established over the past years:

  • Tissue engineering and 3D organotypic disease models, reporter cell lines for analysis of the mechanisms of action of bioactive molecules 
  • Humane cell culture models and co-culture models
  • Platforms for therapeutic peptide and antibody production and in-silico modelling & screening
  • Platform for the development of antiviral therapies
  • Optogenetic engineering of cell lines and receptors

Contact person: Harald Hundsberger

The research focus bioprocess engineering deals with the systematic characterisation of bioreactors (oxygen transfer based on geometries, oxygen transfer matrix and macromixing), the optimisation of bioprocesses for the production of recombinant active substances in bacterial host systems and yeast systems, and the establishment of co-cultivation of extremophilic microorganisms for the extraction of pharmaceutically active secondary metabolites. The following methods and resources have been developed in recent years:

  • Characterisation of bioreactors for fermentation
  • Definition of bioreactor design specifications
  • Optimisation of bioprocesses for the production of recombinant proteins
  • Co-cultivation of microorganisms for the production of biologically active secondary metabolites
  • Biocatalytic reactions

Contact person: Harald Hundsberger

In this research field we deal with the production and synthesis of new materials. One focus will be on renewable raw materials. However, the subject area also allows the use of a variety of other starting materials and the production of further target products. In addition, both starting products and intermediate and end products will be analysed and characterised using the appropriate methods in order to evaluate possible new applications. By dealing with this topic area, we contribute to a positive development of the location and to a further acceptance of sustainable technologies, and position ourselves as an attractive partner for academic institutions and chemical companies.

Contact person: Uwe Rinner

In this research field, we explore how digital transformation can become an integral mechanism for companies to achieve breakthrough innovation and sustainable development.

We support industry partners in assessing and accepting new technologies along the entire value chain to realise the potential of transforming the traditional economy into the digital economy. In addition, we conduct research in the field of organisational development, integration and transformation by analysing and adapting new business models and innovation methods.

Contact person: Deepak Dhungana

This research area focuses on the analysis, design, development and application of software engineering methods and tools for intelligent systems, which incorporate data analytics and artificial intelligence (AI) for the benefit of society and business.

The main objective is to solve challenging (industrial) problems by developing, operating and maintaining software systems that involve complex decision-making processes, using data-driven methods and artificial intelligence as the backbone of the solution architecture. The integration of AI tools into software engineering promises enormous benefits to push the digitalisation wave.

Contact person: Deepak Dhungana

Employees work in the laboratory

Institute of Biotechnology

Research, development and knowledge transfer

We are involved in a steadily growing number of projects conducted in collaboration with research and industry partners from Austria and abroad. This collaborative approach also opens up new opportunities for our students, who are offered places on top-quality PhD programmes as a result of their participation in research partnerships with our institute.


RIZ Mitarbeiterin an einem wissenschaftlichen Analysegerät

Research Institute Krems Bioanalytics

Contract research in the field of biotechnology

Krems Bioanalytics (IKB) is the contract research institute at IMC Krems. The IKB provides contract research for the pharmaceutical industry, biotech companies and academia since 2014. It offers in-depth scientific expertise in hematology, immunology and oncology.


Franz Herzog am Massenspektrometer

Clinical Proteomics Krems endowed professorship

Research using the high-end mass spectrometer

The objective of this endowed professorship is to set up Clinical Proteomics Krems, a research laboratory in which high-resolution mass spectrometry will be used to develop cutting-edge proteomics technologies for biomedical research and patient-specific analysis in clinical studies.


Wissenschaftlicher Mitarbeiter prüft die Einstellungen bei einem wissenschaftlichen Analysegerät

Certificate of compliance with GLP

New therapeutic molecules must meet the safety requirements of regulatory authorities (EMA, FDA) before they are launched to the market. One critical issue is the characterisation of adverse side effects and their negative impact on patients’ health. We have started a long-term collaboration with companies to develop novel technologies and methods for the rapid and reliable testing of adverse side effects in preclinical models and in clinical samples. These technologies must meet the highest quality standards of “Good Laboratory Practice” (GLP), an internationally recognised quality assurance system for laboratory work, inspected by the scope of the Austrian 10 national GLP monitoring programme.

Research projects